Andrew Spencer
About
Andrew Spencer is a scholar working on Hematology, Molecular Biology and Oncology.
According to data from OpenAlex, Andrew Spencer has authored 409 papers receiving a total of 14.4k indexed citations (citations by other indexed papers that have themselves been cited), including 298 papers in Hematology, 203 papers in Molecular Biology and 167 papers in Oncology. Recurrent topics in Andrew Spencer's work include Multiple Myeloma Research and Treatments (246 papers), Protein Degradation and Inhibitors (97 papers) and Peptidase Inhibition and Analysis (64 papers). Andrew Spencer is often cited by papers focused on Multiple Myeloma Research and Treatments (246 papers), Protein Degradation and Inhibitors (97 papers) and Peptidase Inhibition and Analysis (64 papers). Andrew Spencer collaborates with scholars based in Australia, United States and Spain. Andrew Spencer's co-authors include Meletios Α. Dimopoulos, Pieter Sonneveld, Christopher M. Dobson, Tiffany Khong, Vânia Hungria, H. Miles Prince, Robert Knight, Zhinuan Yu, Jerome B. Zeldis and Marta Olesnyckyj and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.
In The Last Decade
Andrew Spencer
390 papers receiving 14.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Andrew Spencer Australia | 57 | 8.4k | 7.2k | 5.7k | 1.3k | 1.2k | 409 | 14.4k | ||
| Edo Vellenga Netherlands | 72 | 7.6k 0.9× | 8.7k 1.2× | 5.3k 0.9× | 3.4k 2.6× | 2.7k 2.3× | 487 | 18.7k | ||
| Hubert Serve Germany | 59 | 8.5k 1.0× | 6.8k 0.9× | 3.1k 0.5× | 1.7k 1.3× | 2.6k 2.3× | 299 | 15.5k | ||
| Carsten Müller‐Tidow Germany | 64 | 11.4k 1.4× | 5.3k 0.7× | 4.3k 0.8× | 2.2k 1.7× | 1.8k 1.6× | 492 | 18.0k | ||
| Peter Schäfer United States | 55 | 4.7k 0.6× | 2.9k 0.4× | 2.6k 0.5× | 2.3k 1.8× | 941 0.8× | 209 | 10.9k | ||
| Bernard Klein France | 72 | 7.4k 0.9× | 6.6k 0.9× | 6.4k 1.1× | 4.8k 3.7× | 1.5k 1.3× | 390 | 17.4k | ||
| Anthony Letai United States | 62 | 12.2k 1.5× | 3.7k 0.5× | 4.5k 0.8× | 2.9k 2.2× | 2.1k 1.8× | 175 | 18.2k | ||
| Ugo Testa Italy | 68 | 8.7k 1.0× | 4.9k 0.7× | 3.0k 0.5× | 3.7k 2.9× | 2.3k 2.0× | 423 | 16.9k | ||
| Wolfgang E. Berdel Germany | 71 | 11.3k 1.4× | 7.3k 1.0× | 5.1k 0.9× | 1.9k 1.5× | 2.5k 2.1× | 502 | 21.3k | ||
| Zwi Berneman Belgium | 53 | 4.8k 0.6× | 2.3k 0.3× | 3.7k 0.6× | 4.6k 3.6× | 1.5k 1.3× | 320 | 13.2k | ||
| Andrew L. Kung United States | 81 | 16.6k 2.0× | 4.1k 0.6× | 6.6k 1.1× | 2.9k 2.2× | 1.6k 1.4× | 285 | 24.2k |
Countries citing papers authored by Andrew Spencer
Since
Specialization
Citations
This map shows the geographic impact of Andrew Spencer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Spencer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Spencer more than expected).
Fields of papers citing papers by Andrew Spencer
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Andrew Spencer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Spencer. The network helps show where Andrew Spencer may publish in the future.
Co-authorship network of co-authors of Andrew Spencer
This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Spencer. A scholar is included among the top collaborators of Andrew Spencer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Spencer. Andrew Spencer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Aoki, Naomi, Wenming Chen, Wee Joo Chng, et al.. (2024). The establishment of a multiple myeloma clinical registry in the Asia–Pacific region: The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR). BMC Medical Research Methodology. 24(1). 102–102.
2.
Khong, Tiffany, Abir Khaled, John Reynolds, et al.. (2024). Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma. Haematologica. 110(3). 764–767.
3.
Barmanray, Rahul, et al.. (2024). Cardiovascular and Metabolic Risk Incidence Among Adult Allogeneic Stem Cell Transplant Recipients: A Narrative Review. Transplantation and Cellular Therapy. 30(10). 970–985.
4.
Rodríguez‐Otero, Paula, Philippe Moreau, Meletios Α. Dimopoulos, et al.. (2024). Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.. Journal of Clinical Oncology. 42(16_suppl). 7502–7502.
5.
Landgren, Ola, Ajai Chari, Yaël C. Cohen, et al.. (2024). Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS. Blood. 145(15). 1658–1669.
6.
Schjesvold, Fredrik, Andrew Spencer, Yaël C. Cohen, et al.. (2023). Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood. 142(Supplement 1). 4752–4752.
7.
Kım, Kihyun, Zoe McQuilten, Peter Mollee, et al.. (2023). A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma. Blood. 142(Supplement 1). 4731–4731.
8.
Kalff, Anna, Peter Mollee, P. Joy Ho, et al.. (2023). The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal. 53(5). 819–824.
9.
Turner, Robert, Hang Quach, Noemi Horvath, et al.. (2023). Response adaptive salvage with KTd and ASCT for functional high‐risk multiple myeloma—The Australasian Leukemia and Lymphoma Group (ALLG ) MM17 Trial. British Journal of Haematology. 202(3). 530–538.
10.
Bergin, Krystal, et al.. (2021). A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16‐02 trial. British Journal of Haematology. 194(3). 580–586.
11.
Ffrench, Rosemary, Maya Korem, David J. Curtis, et al.. (2018). Contemporary analysis of functional immune recovery to opportunistic and vaccine‐preventable infections after allogeneic haemopoietic stem cell transplantation. Clinical & Translational Immunology. 7(10). e1040–e1040.
12.
Chen, Tao, Noah Bell, Patricia D. Finn, et al.. (2018). Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5). Journal of Medicinal Chemistry. 61(17). 7589–7613.
13.
Khong, Tiffany, et al.. (2018). The Canonical Wnt/β-catenin Pathway as a Therapeutic Target in Multiple Myeloma. Archives of Medical Research. 6(7). 1–15.
14.
Khong, Tiffany, et al.. (2017). β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma. Molecular Cancer Therapeutics. 16(9). 1765–1778.
15.
Lipton, Allan, Matthew Smith, Karim Fizazi, et al.. (2016). Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. Clinical Cancer Research. 22(23). 5713–5721.
16.
Spencer, Andrew, Eric D. Labonté, David P. Rosenbaum, et al.. (2014). Intestinal Inhibition of the Na + /H + Exchanger 3 Prevents Cardiorenal Damage in Rats and Inhibits Na + Uptake in Humans. Science Translational Medicine. 6(227). 227ra36–227ra36.
17.
Tan, Peter, et al.. (2013). Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients. Clinical Cancer Research. 20(3). 724–735.
18.
Dawson, Mark A., Stephen Opat, Yamna Taouk, et al.. (2009). Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma. Clinical Cancer Research. 15(2). 714–722.
19.
Wang, Michael, Meletios Α. Dimopoulos, Christine Chen, et al.. (2008). Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 112(12). 4445–4451.
20.
Gass, Jonathan, Michael T. Bethune, Matthew Siegel, Andrew Spencer, & Chaitan Khosla. (2007). Combination Enzyme Therapy for Gastric Digestion of Dietary Gluten in Patients With Celiac Sprue. Gastroenterology. 133(2). 472–480.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Edo Vellenga Breakdown of academic impact, for papers by Hubert Serve Breakdown of academic impact, for papers by Carsten Müller‐Tidow Breakdown of academic impact, for papers by Peter Schäfer Breakdown of academic impact, for papers by Bernard Klein Breakdown of academic impact, for papers by Anthony Letai Breakdown of academic impact, for papers by Ugo Testa Breakdown of academic impact, for papers by Wolfgang E. Berdel Breakdown of academic impact, for papers by Zwi Berneman Breakdown of academic impact, for papers by Andrew L. Kung